RYVU
LIVE

Serial Number

79280613

Owner

Ryvu Therapeutics SA

Attorney

Claudia W. Stangle

Filing Date

Dec 11, 2019

Add to watchlist:

No watchlists yet
View on USPTO

RYVU Trademark

Serial Number: 79280613 • Registration: 6279534

RYVU is a trademark filed by Ryvu Therapeutics SA on December 11, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Ryvu Therapeutics SA (2 trademarks)

ul. Bobrzynskiego 14

Entity Type: 09

Trademark Details

Filing Date

December 11, 2019

Registration Date

March 2, 2021

Published for Opposition

December 15, 2020

Goods & Services

Downloadable computer software for use with medical diagnosis, research, and treatment, namely, for analyzing medical data and diagnosing medical conditions, for evaluation of suggested medical treatment, analyzing and evaluating medical data for mitigation or prevention of disease, for processing data related to clinical trials, and for use with the development, production, and research of pharmaceuticals, namely, data processing, data analysis and data evaluation, processing and analyzing data related to clinical trials, evaluating and analyzing pharmaceutical ingredients and facilitating formulation and administration of pharmaceuticals

Chemico-pharmaceutical preparations, namely, chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer and for use in immunology and oncology; chemical preparations for pharmaceutical purposes for the treatment of cancer and for use in immunology and oncology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of cancer; biotechnological preparations for medical use in the nature of biological preparations for the treatment of cancer and for use immunology and oncology; medicines for human purposes, namely, medicines for the treatment of cancer and for use in immunology and oncology; adjuvants for medical purposes; biological tissue cultures for medical purposes; biological preparations being biological tissue cultures for veterinary purposes; biological preparations for medical purposes, namely, for treatment of cancer and for use in immunology and oncology; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, for treatment of cancer and for use in oncology; diagnostic preparations and materials being diagnostic preparations for medical purposes; chemical preparations for medical purposes namely, for treatment of cancer and for use in immunology and oncology; immunomodulators being a type of pharmaceutical preparation for the treatment of cancer; immunostimulants; immunoassay reagents for medical use; chemotherapeutics; chemical reagents for medical or veterinary purposes; biological preparations for the treatment of cancer; mixed biological preparations for medical purposes, namely, for the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations and substances, namely, for treatment of cancer and for use in immunology and oncology; anti-cancer preparations

Research and development services in the field of immunology; chemistry services, namely, research in the field of immunology and oncology; chemical laboratories; chemistry consultation; testing of chemicals; chemical analysis; scientific research relating to chemistry; chemical research laboratory services; research and development services in the field of chemistry; provision of scientific information relating to the chemical industry; preparation of reports relating to chemical research; research and development in the pharmaceutical and biotechnology fields; laboratory research services relating to pharmaceuticals; information technology consultancy services for the pharmaceutical and healthcare industries; scientific research; computer aided scientific research services; biochemical research and analysis; genetic research; clinical research in the field of immunology and oncology; biological research; biological analysis; scientific research relating to biology; custom development of biological samples for research purposes; medical research; research to develop new products; research in the field of gene therapy; research and development in the field of diagnostic preparations; information on the subject of scientific research in the field of biochemistry and biotechnology; consultancy relating to pharmaceutical research; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; research on the subject of pharmaceuticals; scientific laboratory services; scientific research services relating to the isolation and cultivation of human tissues and cells; computer aided scientific testing in the field of immunology and oncology; scientific and technological design, namely, design in the fields of biochemistry and biotechnology, namely, custom design of pharmaceuticals, chemicals, biological preparations, scientific software, pharmaceutical software, medical software, medical instruments and devices; software design and development; design and development of medical technology, namely, technology research in the field of medical instruments and devices; design and development of software for database management; pharmaceutical research and development; providing scientific information about the results of clinical trials for pharmaceutical products; technological research, namely, research in the field of pharmaceuticals; engineering services relating to computers, namely, computer-aided engineering services for the biotechnology industry; computer systems analysis

Chemical preparations being additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical products for biotechnological purposes, namely, chemicals for use in biotechnological research and product development; chemicals for use in the agrochemical industry

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 2, 2026 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 20, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 2, 2021 FICS
FINAL DISPOSITION PROCESSED
Jun 2, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 2, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 2, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Dec 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 25, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 11, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 11, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 11, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 11, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 11, 2020 CNEA
EXAMINER'S AMENDMENT ENTERED
Oct 21, 2020 XAEC
ASSIGNED TO LIE
Oct 20, 2020 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 20, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 20, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 20, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 8, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 8, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 8, 2020 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 6, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 6, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 6, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 6, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 6, 2020 COAR
REFUSAL PROCESSED BY IB
Apr 24, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 8, 2020 RFCS
REFUSAL PROCESSED BY MPU
Apr 8, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 20, 2020 RFCR
NON-FINAL ACTION WRITTEN
Mar 19, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 17, 2020 MAFR
ASSIGNED TO EXAMINER
Mar 13, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 12, 2020 REPR